Global Pharmaceutical Organisation

Capability Architecture & Operating Model Alignment

A multinational pharmaceutical organisation with a workforce of approximately 46,000 and operations spanning the United States, Europe, and the Middle East sought to realign leadership priorities, organisational capability, and operating model design in the face of rapid innovation demands, regulatory complexity, and competitive pressures.

The organisation was pursuing simultaneous strategic objectives: accelerated R&D productivity, improved cross-functional integration between commercial and regulatory units, and enhanced executive coherence on enterprise-wide transformation initiatives. These ambitions placed elevated scrutiny on governance effectiveness, leadership clarity, and accountability around performance outcomes.

Mandate

The CEO and Executive Committee engaged strategic advisory to:

Reduce capability fragmentation across divisional and functional clusters
Align leadership priorities globally across R&D, manufacturing, commercial, and corporate units
Embed accountability and performance governance into executive and board reporting
Define a sustainable operating model that supports innovation delivery, regulatory compliance, and enterprise resilience

Approach

The engagement proceeded through three phases:

1. Diagnostic & Capability Mapping:
- Comprehensive assessment of leadership capability, organisational structures, and critical capability gaps was conducted across all major functions and regions.
2. Governance & Operating Model Design:
- Co-creation of a future-ready operating model, clarifying roles, decision rights, escalation protocols, and cross-functional interfaces, aligned to strategic priorities and regulatory imperatives.
3. Executive Alignment & Embedding:
- Facilitated executive workshops and governance sessions to embed agreed priorities, reinforce performance accountability, and support transition planning for critical leadership pathways.

Outcomes

These outcomes reflect aggregate performance impacts across the engagement’s 12-month span:

29% reduction in critical capability gaps across priority domains
1,100+ senior leaders aligned through structured executive sessions
Operational clarity achieved across 8 global business units
Enterprise-wide governance and performance metrics embedded into executive and board reporting cycles
Enhanced integration between strategic planning, compliance oversight, and global delivery execution

Impact on Institutional Performance

The engagement reinforced the organisation’s capacity to:

Navigate regulatory complexity with clear leadership accountability
Accelerate innovation delivery by aligning R&D, commercial, and regulatory functions
Strengthen governance structures supporting enterprise resilience and risk oversight
Support long-term strategic coherence in a competitive global pharmaceutical landscape

Role

Senior transformation and governance advisor to the CEO and Executive Committee, working closely with the Chief Operating Officer, Head of Global Strategy, and Board Governance Committee.